Sanofi (SNY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 55.50 |
| Open | 54.88 |
| Bid | 55.17 x 1000 |
| Ask | 55.50 x 3200 |
| Day's Range | 54.64 - 55.21 |
| 52 Week Range | 46.93 - 58.10 |
| Volume | |
| Avg. Volume | 2,277,998 |
| Market Cap | 138.102B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 19.47 |
| EPS (TTM) | 2.83 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.80 (3.24%) |
| Ex-Dividend Date | May 26, 2022 |
| 1y Target Est | 70.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SNY
Related Research
- SanofiAnalyst Report: SanofiSanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.RatingFair ValueEconomic Moat2 days agoMorningstar
- Motley Fool
3 Unstoppable Stocks That Are Higher Than Before the Market Correction
Over the past six months, the market has fallen sharply thanks to a toxic combination of fears about a looming recession, rising inflation, and rising interest rates. Growth stocks and unprofitable companies have been especially hard hit. Sanofi (NASDAQ: SNY) is a multinational pharma giant with a market cap in excess of $135 billion, and its shares are up by over 17% from six months ago.
- Zacks
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
- Zacks
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
